Cardiovascular

Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Metformin and lifestyle changes show no significant impact on atrial fibrillation (AFib) burden or progression compared with standard care.

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).

Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.

Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.

New study findings reveal that the risk of cardiovascular disease among light ex-smokers aligns quickly with never-smokers, while heavy ex-smokers may take over 25 years to reach the same level.

A new study has linked work-related stress to poorer cardiovascular health, highlighting the need for workplace wellness programs to reduce the risk of cardiovascular disease.

A new study assesses the prognostic accuracy of Predicting Risk of CVD EVENTs (PREVENT) equations for predicting cardiovascular disease (CVD) mortality in the US population.

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.

This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.

Hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, and severe preeclampsia significantly elevate cardiovascular risk during delivery, study finds.

Despite reductions in deaths from cancer and cardiovascular diseases, increased mortality from assaults, accidents, and the COVID-19 pandemic has widened disparities in health outcomes for Black individuals.

Laurence Sperling, MD, executive director of the Million Hearts initiative at the CDC and CMS, shared insight into population health strategies to address cardiovascular disease (CVD) prevention in at-risk populations.

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.

September 24 celebrates Familial Hypercholesterolemia Awareness Day, which recognizes the importance of screening measures, education, and advocacy in a lesser-known, underdiagnosed cardiovascular condition.

On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.

Spouses and first-degree relatives of patients with genitourinary (GU) cancers face increased risks of developing cardiovascular and psychological comorbidities, particularly within the first year of diagnosis.

Ty J. Gluckman, MD, FACC, FAHA, of Providence St. Joseph Health, emphasizes the need for better prevention of cardiovascular risks and discusses upcoming advances in glucagon-like peptide 1 (GLP-1) therapies.

Joseph Biggio, MD, system chair and service line leader for women's services and system chair for maternal fetal medicine at Ochsner Health, discusses some of the innovations to manage hypertension during pregnancy and postpartum.

Ty J. Gluckman, MD, FACC, FAHA, of Providence St. Joseph Health, reacted positively to CMS' drug price cuts under the Inflation Reduction Act, but he also expressed concerns about the potential future impact on drug innovation.